FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022609820> ?p ?o ?g. }

• W2022609820 endingPage "1263" @default.
• W2022609820 startingPage "1259" @default.
• W2022609820 abstract "Head and neck squamous cell cancers (HNSCC) are particularly aggressive and are resistant to many forms of treatment. Ceramide metabolism has been shown to play an important role in cancer progression and cancer resistance to therapy in many tumor models, including HNSCC. Here, we study the role of the ceramide-metabolizing enzyme acid ceramidase (AC) in therapeutic responses in HNSCC. First, we show that AC is over-expressed in 70% of head and neck squamous cell tumors compared with normal tissues, suggesting that this enzyme may play an important role in facilitating HNSCC growth. Next, comparison of three HNSCC cell lines with low, medium, and high levels of AC reveals an inverse correlation between the levels of AC and their response to exogenous C-6-ceramide. Furthermore, over-expression of AC in SCC-1 cells increased resistance to Fas-induced cell killing. Conversely, down-regulation of AC using specific AC small interfering RNA (siRNA) sensitized the SCC-1 cancer cell line to Fas-induced apoptosis. Finally, we show that the AC inhibitor LCL 204 can sensitize HNSCC cell lines to Fas-induced apoptosis both in vitro and in a xenograft model in vivo, suggesting that the combination of FasL gene therapy and LCL 204 may become a new treatment option for advanced-stage head and neck cancer. Head and neck squamous cell cancers (HNSCC) are particularly aggressive and are resistant to many forms of treatment. Ceramide metabolism has been shown to play an important role in cancer progression and cancer resistance to therapy in many tumor models, including HNSCC. Here, we study the role of the ceramide-metabolizing enzyme acid ceramidase (AC) in therapeutic responses in HNSCC. First, we show that AC is over-expressed in 70% of head and neck squamous cell tumors compared with normal tissues, suggesting that this enzyme may play an important role in facilitating HNSCC growth. Next, comparison of three HNSCC cell lines with low, medium, and high levels of AC reveals an inverse correlation between the levels of AC and their response to exogenous C-6-ceramide. Furthermore, over-expression of AC in SCC-1 cells increased resistance to Fas-induced cell killing. Conversely, down-regulation of AC using specific AC small interfering RNA (siRNA) sensitized the SCC-1 cancer cell line to Fas-induced apoptosis. Finally, we show that the AC inhibitor LCL 204 can sensitize HNSCC cell lines to Fas-induced apoptosis both in vitro and in a xenograft model in vivo, suggesting that the combination of FasL gene therapy and LCL 204 may become a new treatment option for advanced-stage head and neck cancer." @default.
• W2022609820 created "2016-06-24" @default.
• W2022609820 creator A5000955921 @default.
• W2022609820 creator A5003455185 @default.
• W2022609820 creator A5008051755 @default.
• W2022609820 creator A5008423568 @default.
• W2022609820 creator A5023706400 @default.
• W2022609820 creator A5032795878 @default.
• W2022609820 creator A5035736473 @default.
• W2022609820 creator A5050483245 @default.
• W2022609820 creator A5056448190 @default.
• W2022609820 creator A5067753257 @default.
• W2022609820 creator A5076524129 @default.
• W2022609820 creator A5084557253 @default.
• W2022609820 creator A5090422329 @default.
• W2022609820 creator A5068504033 @default.
• W2022609820 creator A5072009493 @default.
• W2022609820 creator A5087577624 @default.
• W2022609820 date "2007-07-01" @default.
• W2022609820 modified "2023-10-14" @default.
• W2022609820 title "Role of Acid Ceramidase in Resistance to FasL: Therapeutic Approaches Based on Acid Ceramidase Inhibitors and FasL Gene Therapy" @default.
• W2022609820 cites W1965026478 @default.
• W2022609820 cites W1977644244 @default.
• W2022609820 cites W1983347881 @default.
• W2022609820 cites W1986648791 @default.
• W2022609820 cites W1988009341 @default.
• W2022609820 cites W1993691675 @default.
• W2022609820 cites W2007222184 @default.
• W2022609820 cites W2009059721 @default.
• W2022609820 cites W2009155924 @default.
• W2022609820 cites W2029641949 @default.
• W2022609820 cites W2031449170 @default.
• W2022609820 cites W2039585726 @default.
• W2022609820 cites W2054778180 @default.
• W2022609820 cites W2059246206 @default.
• W2022609820 cites W2073096708 @default.
• W2022609820 cites W2076269247 @default.
• W2022609820 cites W2087065359 @default.
• W2022609820 cites W2094570524 @default.
• W2022609820 cites W2112733125 @default.
• W2022609820 cites W2123149430 @default.
• W2022609820 cites W51229851 @default.
• W2022609820 doi "https://doi.org/10.1038/sj.mt.6300167" @default.
• W2022609820 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17426710" @default.
• W2022609820 hasPublicationYear "2007" @default.
• W2022609820 type Work @default.
• W2022609820 sameAs 2022609820 @default.
• W2022609820 citedByCount "83" @default.
• W2022609820 countsByYear W20226098202012 @default.
• W2022609820 countsByYear W20226098202013 @default.
• W2022609820 countsByYear W20226098202014 @default.
• W2022609820 countsByYear W20226098202015 @default.
• W2022609820 countsByYear W20226098202016 @default.
• W2022609820 countsByYear W20226098202017 @default.
• W2022609820 countsByYear W20226098202018 @default.
• W2022609820 countsByYear W20226098202019 @default.
• W2022609820 countsByYear W20226098202020 @default.
• W2022609820 countsByYear W20226098202021 @default.
• W2022609820 countsByYear W20226098202023 @default.
• W2022609820 crossrefType "journal-article" @default.
• W2022609820 hasAuthorship W2022609820A5000955921 @default.
• W2022609820 hasAuthorship W2022609820A5003455185 @default.
• W2022609820 hasAuthorship W2022609820A5008051755 @default.
• W2022609820 hasAuthorship W2022609820A5008423568 @default.
• W2022609820 hasAuthorship W2022609820A5023706400 @default.
• W2022609820 hasAuthorship W2022609820A5032795878 @default.
• W2022609820 hasAuthorship W2022609820A5035736473 @default.
• W2022609820 hasAuthorship W2022609820A5050483245 @default.
• W2022609820 hasAuthorship W2022609820A5056448190 @default.
• W2022609820 hasAuthorship W2022609820A5067753257 @default.
• W2022609820 hasAuthorship W2022609820A5068504033 @default.
• W2022609820 hasAuthorship W2022609820A5072009493 @default.
• W2022609820 hasAuthorship W2022609820A5076524129 @default.
• W2022609820 hasAuthorship W2022609820A5084557253 @default.
• W2022609820 hasAuthorship W2022609820A5087577624 @default.
• W2022609820 hasAuthorship W2022609820A5090422329 @default.
• W2022609820 hasBestOaLocation W20226098201 @default.
• W2022609820 hasConcept C121608353 @default.
• W2022609820 hasConcept C126322002 @default.
• W2022609820 hasConcept C190283241 @default.
• W2022609820 hasConcept C2776530083 @default.
• W2022609820 hasConcept C2776833033 @default.
• W2022609820 hasConcept C2777851122 @default.
• W2022609820 hasConcept C2779237115 @default.
• W2022609820 hasConcept C502942594 @default.
• W2022609820 hasConcept C55493867 @default.
• W2022609820 hasConcept C71924100 @default.
• W2022609820 hasConcept C86803240 @default.
• W2022609820 hasConcept C96232424 @default.
• W2022609820 hasConceptScore W2022609820C121608353 @default.
• W2022609820 hasConceptScore W2022609820C126322002 @default.
• W2022609820 hasConceptScore W2022609820C190283241 @default.
• W2022609820 hasConceptScore W2022609820C2776530083 @default.
• W2022609820 hasConceptScore W2022609820C2776833033 @default.
• W2022609820 hasConceptScore W2022609820C2777851122 @default.
• W2022609820 hasConceptScore W2022609820C2779237115 @default.
• W2022609820 hasConceptScore W2022609820C502942594 @default.
• W2022609820 hasConceptScore W2022609820C55493867 @default.

• next